科倫藥業(002422.SZ):雅安國資公司擬增持5000萬元-9900萬元公司股份
格隆匯2月28日丨科倫藥業(002422.SZ)公佈,公司於近日收到持股5%以上股東雅安市國有資產經營有限責任公司(簡稱“雅安國資公司”)通知,雅安國資公司擬於公告日起六個月內通過深圳證券交易所允許的方式增持公司股份(擬增持價格不超過37.60元/股),本次增持金額不低於5,000萬元人民幣(含本數),且不超過9,900萬元人民幣(含本數),具體增持資金總額以實際使用的資金總額爲準。
本次增持資金爲雅安國資公司自有資金與專項貸款。中國工商銀行股份有限公司四川省分行已向雅安國資公司出具《中國工商銀行股份有限公司四川省分行貸款承諾書》,中國工商銀行股份有限公司四川省分行本次爲雅安國資公司增持公司股份提供貸款專項資金不超過人民幣8,910萬元(含),且貸款金額不超過實際增持金額的90%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.